Cargando…

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the “cancer-immunity cycle” in the pan-cancer setting in order to understand the immune landscape of metastati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Shumei, Okamura, Ryosuke, Kumaki, Yuichi, Ikeda, Sadakatsu, Nikanjam, Mina, Eskander, Ramez, Goodman, Aaron, Lee, Suzanna, Glenn, Sean T., Dressman, Devin, Papanicolau-Sengos, Antonios, Lenzo, Felicia L., Morrison, Carl, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028323/ https://www.ncbi.nlm.nih.gov/pubmed/32117584 http://dx.doi.org/10.1080/2162402X.2019.1708065

Ejemplares similares

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
por: Kato, Shumei, et al.
Publicado: (2021)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma
por: Hu, Ying, et al.
Publicado: (2020)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
por: Khemlina, Galina, et al.
Publicado: (2017)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience
por: Nikanjam, Mina, et al.
Publicado: (2018)

Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms
por: Eskander, Ramez N., et al.
Publicado: (2020)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
por: Kato, Shumei, et al.
Publicado: (2020)

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions
por: Kobayashi, Yukari, et al.
Publicado: (2020)

VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma
por: Tinca, Andreea Cătălina, et al.
Publicado: (2022)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021)

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
por: Jardim, Denis L., et al.
Publicado: (2020)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
por: Kumaki, Yuichi, et al.
Publicado: (2023)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7uvdm64hqoltk5im78cv0pkhq4